Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03673787 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of Ipatasertib in Combination With Atezolizumab

Study acronym: IceCAP
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 14, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 2023 to Mar 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v7
  2. Primary completion date: Jul 2022 to Nov 2023
    • Study completion date: Nov 2022 to Nov 2023
    • Study description expanded, about 12 words
    v6
  3. Enrollment target: 51 to 87
    • Study description expanded, about 52 words
    v5
  4. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Jul 2020 to Jul 2022
    • Study completion date: Nov 2020 to Nov 2022
    • Site details revised
    v4
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B). Part A, will determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). This will be followed by the Part B dose expansion phase to further characterise the safety and tolerability and to assess the pharmacodynamic activity of the combination.
Trial Details
NCT Number NCT03673787
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Hoffmann-La Roche
Conditions
(from sponsor)		 Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
Related terms Glioblastoma
Enrollment 87 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov